Provider
Diagenics International Corporation Ernest Kapetanovic - CEO CopyrightAll rights reserved to Diagenics SE. The texts, images, graphics, audio and video recordings and animations as well as their arrangement on the Diagenics website are all subject to copyright protection and other intellectual property protection. These objects may not be copied for commercial use or distribution, nor may these objects be modified or reposted on other web sites. The Diagenics website also contains images that are subject to the copyright protection of their providers. Forward-Looking StatementsThis website contains forward-looking statements that are based on the beliefs of Diagenics’ management. When used in this website, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are used to identify forward-looking statements. Such statements reflect the views of Diagenics as of the date made with respect to future events and are subject to risks and uncertainties. Many factors could cause actual results to be different from those projected here, including, among others, changes in general economic and business conditions, changes in currency exchange rates and interest rates, end or reduction of patent rights for our products and changes in business strategy. Diagenics disclaims any intention or obligation to update these forward-looking statements. Privacy StatementDiagenics appreciates your interest in our company and your visiting our website. Your privacy is important to us and we want you to feel comfortable visiting our sites. The protection of your privacy in the processing of your personal data is an important concern to which we pay special attention during our business processes. Personal data collected during visits to our Web sites are processed by us according to the legal provisions valid for the countries in which the websites are maintained. The Diagenics websites may include, however, links to other websites which are not covered by this privacy statement. SecurityDiagenics uses technical and organizational security measures in order to protect the data we have under our control against accidental or intentional manipulation, loss, destruction or against access by unauthorized persons. Our security procedures are continually enhanced as new technology becomes available. |
||||||||||||||
Produkte
DIACORDON - POCT
POINT-OF-CARE TEST
The Point Of Care Test (POCT) is the successor of the ELISA Test and an important supplement for the emergency ambulances. It is a quick and qualitative test for making the first decisions. Point Of Care Tests are always advantageous, since they can provide a diagnosis without the laboratory support.
DIACORDON™ POCT is a stripe test (lateral flow), which also functions on the GPBB basis. Its various layers are plated with small traces of monoclonal catch-antibody of GPBB. Another antibody, responsible for the colouring, is applied on the other side. Once the blood sample runs on the absorbent strap on the antibody track, GPBB is caught by the antibodies and made visible with the help of the antibody colouring. 50 µl are enough to gain a solid result. The time for testing only takes about 15 minutes.
Until now there is no early and reliable heart specific test. Therefore, it is very difficult for doctors to rule out an infarction incidence without invasive diagnostics. Diagenics offers its patented GPBB blood test for an indication group, which knows no other alternatives. Thus, DIACORDON™ is progressive in the field of heart diseases diagnostics.
Another interesting patient group endorses those who had an open heart operation and who often suffer from a destruction of the heart muscle cells under use of a heart-lung machine. DIACORDON™ can help monitoring these patients within the first 12 to 18 hours (as long as GPBB is traceable) after the operation.
The well defined goal of Diagenics is to establish DIACORDON™ as a “gold standard” for the diagnosis and monitoring of myocardial ischemia. Once the first results can be confirmed, the test can be initiated for use as a rapid test in ambulances, in emergency rooms, in doctor offices or next to the patient bed.
The test is simple, fast, safe, dependable and sensitive. At the moment there are discussions with leading active pharmaceutical companies concerning its marketing worldwide.
DIACORDON - ELISA
LABORATORY TEST
DIACORDON™ is a blood test for the early detection of cardiac infarction. It works on an enzyme basis and can detect Glycogen-Phosphorylase Isoenzym BB (GPBB) via an antibody owned by Diagenics.
The enzyme GPBB enters the bloodstream as soon as a myocardial ischemia occurs. In the long run such an insufficient oxygen supply leads to a necrosis of the affected cells and/or eventually to an infarction. Moreover, the detection of GPBB in the blood provides information about the progress of the coronary syndromes (including unstable angina pectoris) and classic cases of heart attack. In this way it contributes decisively to the diagnosis of heart infarction patients.
There are already markers, such as myoglobin and troponin, which contribute to the diagnosis and are routinely applied in cases of a myocardial infarction. Myoglobin, however, has the disadvantage of not being heart specific. It can also be detected after damages of the skeletal muscles or after acute renal failure and thus does not give a clear answer. Troponin, on the other hand, is heart specific, but can only be detected three to six hours after the first symptoms (chest pain).
GPBB is not only heart specific but also early detectable, i.e. within the first hour. For the case of acute coronary syndromes this is a vital advantage, since a quick and exact diagnosis can save lives.
|
About us
|
|
